دورية أكاديمية
أعرض في EDS

Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema.

التفاصيل البيبلوغرافية
العنوان: Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema.
المؤلفون: Murphy E; CSL Behring King of Prussia Pennsylvania., Donahue C; CSL Behring King of Prussia Pennsylvania., Omert L; CSL Behring King of Prussia Pennsylvania., Persons S; Allergy, Asthma, Immunology Medical Care Portland Oregon., Tyma TJ; Asthma, Allergy & Immunology Associates, Ltd. Scottsdale Arizona., Chiao J; CSL Behring King of Prussia Pennsylvania., Lumry W; AARA Research Center Dallas Texas.
المصدر: Nursing open [Nurs Open] 2018 Aug 28; Vol. 6 (1), pp. 126-135. Date of Electronic Publication: 2018 Aug 28 (Print Publication: 2019).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101675107 Publication Model: eCollection Cited Medium: Print ISSN: 2054-1058 (Print) Linking ISSN: 20541058 NLM ISO Abbreviation: Nurs Open Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Hoboken, NJ] : John Wiley & Sons, Inc., [2014]-
مستخلص: Aims: The aim of this study was to provide recommendations for training patients with hereditary angioedema, based on nursing clinical trial experience, to self-administer subcutaneous C1-INH (C1-INH[SC]) used as routine prophylaxis.
Background: A volume-reduced, subcutaneous C1-INH concentrate (C1-INH(SC); HAEGARDA®; CSL Behring) was recently FDA-approved for the routine prevention of hereditary angioedema attacks. Nurses will play an important role in patient training.
Design: Review of a phase 3, randomized, placebo-controlled, double-blind, crossover trial of C1-INH(SC) (COMPACT) and summary of recommendations for training patients based on nurses' "hands-on experience."
Methods: A panel of nurses with clinical trial experience provided recommendations for patient training.
Results: Practical suggestions and guidelines were compiled regarding patient selection, product reconstitution and administration and patient follow-up. Successful patient self-administration of C1-INH(SC) can be greatly facilitated by qualified nursing intervention. The information provided in this paper will be useful to nurses anywhere who have an opportunity to interact with patients dealing with hereditary angioedema.
References: World Allergy Organ J. 2012 Dec;5(12):182-99. (PMID: 23282420)
J Allergy Clin Immunol. 2012 Sep;130(3):692-7. (PMID: 22841766)
Orphanet J Rare Dis. 2014 Jul 04;9:99. (PMID: 24996814)
Transfusion. 2016 May;56(5):1022-9. (PMID: 26756974)
Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):22. (PMID: 20667125)
Allergy. 2012 Feb;67(2):147-57. (PMID: 22126399)
J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):77-84. (PMID: 24565773)
Am J Gastroenterol. 2006 Mar;101(3):619-27. (PMID: 16464219)
Allergy Asthma Proc. 2015 Mar-Apr;36(2):145-50. (PMID: 25715243)
Nurs Open. 2018 Aug 28;6(1):126-135. (PMID: 30534402)
Ann Allergy Asthma Immunol. 2017 Jul;119(1):59-64. (PMID: 28668241)
Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):21. (PMID: 20667124)
Allergy Asthma Proc. 2012 Nov-Dec;33 Suppl 1:S145-56. (PMID: 23394603)
Int Arch Allergy Immunol. 2013;161 Suppl 1:17-20. (PMID: 23689240)
Am J Med. 2006 Mar;119(3):267-74. (PMID: 16490473)
Allergy Asthma Proc. 2014 Jan-Feb;35(1):47-53. (PMID: 24268449)
J Infus Nurs. 2014 Jul-Aug;37(4):284-90. (PMID: 24983261)
Ann Allergy Asthma Immunol. 2015 Apr;114(4):281-288.e7. (PMID: 25707325)
Patient Prefer Adherence. 2016 Sep 07;10:1727-37. (PMID: 27660422)
Allergy. 2014 May;69(5):602-16. (PMID: 24673465)
Allergy Asthma Proc. 2010 Sep-Oct;31(5):407-14. (PMID: 20929608)
Ann Allergy Asthma Immunol. 2014 Apr;112(4):371-5. (PMID: 24428960)
Immunotherapy. 2014;6(5):533-51. (PMID: 24635050)
Clin Exp Immunol. 2014 Jan;175(1):59-67. (PMID: 23786259)
J Allergy Clin Immunol Pract. 2013 Sep-Oct;1(5):458-67. (PMID: 24565617)
N Engl J Med. 2010 Aug 5;363(6):513-22. (PMID: 20818886)
Allergy Asthma Proc. 2013 Jan-Feb;34(1):3-6. (PMID: 23406927)
Clin Rev Allergy Immunol. 2016 Oct;51(2):216-29. (PMID: 27459852)
Allergy. 2018 Aug;73(8):1575-1596. (PMID: 29318628)
Eur J Dermatol. 2009 Mar-Apr;19(2):147-51. (PMID: 19264579)
Int Arch Allergy Immunol. 2013;161 Suppl 1:21-5. (PMID: 23689241)
Ann Allergy Asthma Immunol. 2012 Dec;109(6):395-402. (PMID: 23176876)
J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):963-71. (PMID: 27286778)
J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):220-7. (PMID: 25609328)
Allergy Asthma Proc. 2014 Sep-Oct;35(5):371-6. (PMID: 25295804)
Ann Allergy Asthma Immunol. 2013 Nov;111(5):329-36. (PMID: 24125136)
Int Arch Allergy Immunol. 2013;161 Suppl 1:10-6. (PMID: 23689239)
Allergy. 2015 Oct;70(10):1319-28. (PMID: 26016741)
Allergy Asthma Proc. 2015 May-Jun;36(3):213-7. (PMID: 25976438)
N Engl J Med. 2017 Mar 23;376(12):1131-1140. (PMID: 28328347)
J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):948-955.e15. (PMID: 27329469)
J Infus Nurs. 2014 Jan-Feb;37(1):29-34. (PMID: 24384882)
فهرسة مساهمة: Keywords: C1‐INH(SC); C1‐inhibitor; HAEGARDA; hereditary angioedema; prophylaxis; self‐administration; subcutaneous
تواريخ الأحداث: Date Created: 20181212 Latest Revision: 20231004
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC6279717
DOI: 10.1002/nop2.194
PMID: 30534402
قاعدة البيانات: MEDLINE
الوصف
تدمد:2054-1058
DOI:10.1002/nop2.194